AACR-FDA-NCI cancer biomarkers collaborative consensus report: Advancing the use of biomarkers in cancer drug development

Samir N. Khleif, James H. Doroshow, William N. Hait

Research output: Contribution to journalReview article

134 Citations (Scopus)

Abstract

Recent discoveries in cancer biology have greatly increased our understanding of cancer at the molecular and cellular level, but translating this knowledge into safe and effective therapies for cancer patients has proved to be challenging. There is a growing imperative to modernize the drug development process by incorporating new techniques that can predict the safety and effectiveness of new drugs faster, with more certainty, and at lower cost. Biomarkers are central to accelerating the identification and adoption of new therapies, but currently, many barriers impede their use in drug development and clinical practice. In 2007, the AACR-FDA-NCI Cancer Biomarkers Collaborative stepped into the national effort to bring together disparate stakeholders to clearly delineate these barriers, to develop recommendations for integrating biomarkers into the cancer drug development enterprise, and to set in motion the necessary action plans and collaborations to see the promise of biomarkers come to fruition, efficiently delivering quality cancer care to patients.

Original languageEnglish (US)
Pages (from-to)3299-3318
Number of pages20
JournalClinical Cancer Research
Volume16
Issue number13
DOIs
StatePublished - Jul 1 2010

Fingerprint

Tumor Biomarkers
Pharmaceutical Preparations
Neoplasms
Biomarkers
Quality of Health Care
Safety
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

AACR-FDA-NCI cancer biomarkers collaborative consensus report : Advancing the use of biomarkers in cancer drug development. / Khleif, Samir N.; Doroshow, James H.; Hait, William N.

In: Clinical Cancer Research, Vol. 16, No. 13, 01.07.2010, p. 3299-3318.

Research output: Contribution to journalReview article

Khleif, Samir N. ; Doroshow, James H. ; Hait, William N. / AACR-FDA-NCI cancer biomarkers collaborative consensus report : Advancing the use of biomarkers in cancer drug development. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 13. pp. 3299-3318.
@article{2f7902d687694116950a379af1795ad4,
title = "AACR-FDA-NCI cancer biomarkers collaborative consensus report: Advancing the use of biomarkers in cancer drug development",
abstract = "Recent discoveries in cancer biology have greatly increased our understanding of cancer at the molecular and cellular level, but translating this knowledge into safe and effective therapies for cancer patients has proved to be challenging. There is a growing imperative to modernize the drug development process by incorporating new techniques that can predict the safety and effectiveness of new drugs faster, with more certainty, and at lower cost. Biomarkers are central to accelerating the identification and adoption of new therapies, but currently, many barriers impede their use in drug development and clinical practice. In 2007, the AACR-FDA-NCI Cancer Biomarkers Collaborative stepped into the national effort to bring together disparate stakeholders to clearly delineate these barriers, to develop recommendations for integrating biomarkers into the cancer drug development enterprise, and to set in motion the necessary action plans and collaborations to see the promise of biomarkers come to fruition, efficiently delivering quality cancer care to patients.",
author = "Khleif, {Samir N.} and Doroshow, {James H.} and Hait, {William N.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-10-0880",
language = "English (US)",
volume = "16",
pages = "3299--3318",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - AACR-FDA-NCI cancer biomarkers collaborative consensus report

T2 - Advancing the use of biomarkers in cancer drug development

AU - Khleif, Samir N.

AU - Doroshow, James H.

AU - Hait, William N.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Recent discoveries in cancer biology have greatly increased our understanding of cancer at the molecular and cellular level, but translating this knowledge into safe and effective therapies for cancer patients has proved to be challenging. There is a growing imperative to modernize the drug development process by incorporating new techniques that can predict the safety and effectiveness of new drugs faster, with more certainty, and at lower cost. Biomarkers are central to accelerating the identification and adoption of new therapies, but currently, many barriers impede their use in drug development and clinical practice. In 2007, the AACR-FDA-NCI Cancer Biomarkers Collaborative stepped into the national effort to bring together disparate stakeholders to clearly delineate these barriers, to develop recommendations for integrating biomarkers into the cancer drug development enterprise, and to set in motion the necessary action plans and collaborations to see the promise of biomarkers come to fruition, efficiently delivering quality cancer care to patients.

AB - Recent discoveries in cancer biology have greatly increased our understanding of cancer at the molecular and cellular level, but translating this knowledge into safe and effective therapies for cancer patients has proved to be challenging. There is a growing imperative to modernize the drug development process by incorporating new techniques that can predict the safety and effectiveness of new drugs faster, with more certainty, and at lower cost. Biomarkers are central to accelerating the identification and adoption of new therapies, but currently, many barriers impede their use in drug development and clinical practice. In 2007, the AACR-FDA-NCI Cancer Biomarkers Collaborative stepped into the national effort to bring together disparate stakeholders to clearly delineate these barriers, to develop recommendations for integrating biomarkers into the cancer drug development enterprise, and to set in motion the necessary action plans and collaborations to see the promise of biomarkers come to fruition, efficiently delivering quality cancer care to patients.

UR - http://www.scopus.com/inward/record.url?scp=77954241248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954241248&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-0880

DO - 10.1158/1078-0432.CCR-10-0880

M3 - Review article

C2 - 20501613

AN - SCOPUS:77954241248

VL - 16

SP - 3299

EP - 3318

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -